EP3938519A1 - Surexpression du transporteur fumarate-succinate dans la levure pour augmenter la production d'éthanol et réduire la production d'acétate - Google Patents

Surexpression du transporteur fumarate-succinate dans la levure pour augmenter la production d'éthanol et réduire la production d'acétate

Info

Publication number
EP3938519A1
EP3938519A1 EP20718458.1A EP20718458A EP3938519A1 EP 3938519 A1 EP3938519 A1 EP 3938519A1 EP 20718458 A EP20718458 A EP 20718458A EP 3938519 A1 EP3938519 A1 EP 3938519A1
Authority
EP
European Patent Office
Prior art keywords
cells
sfc1
yeast
modified
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20718458.1A
Other languages
German (de)
English (en)
Inventor
Elizabeth A. KRASLEY
Zhongqiang Chen
Lori Ann Maggio-Hall
Quinn Qun Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Danisco US Inc
Original Assignee
Danisco US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danisco US Inc filed Critical Danisco US Inc
Publication of EP3938519A1 publication Critical patent/EP3938519A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
    • C12P7/04—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
    • C12P7/06—Ethanol, i.e. non-beverage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/10—Biofuels, e.g. bio-diesel

Definitions

  • compositions and methods relate to modified yeast that over-expresses fumarate-succinate transporter.
  • the yeast produces an increased amount of ethanol and decreased amount of acetate compared to parental cells.
  • Such yeast is particularly useful for large-scale ethanol production from starch substrates.
  • First-generation yeast-based ethanol production converts sugars into fuel ethanol.
  • Acetate is not a desirable by-product as it has negative effects on yeast growth and fermentation.
  • acetate reduces the pH of left-over water from fermentation and distillation, referred to as backset, which is typically reused for liquefaction of a subsequent batch of substrate.
  • backset the pH of left-over water from fermentation and distillation
  • ethanol producers must adjust the pH of the backset (or liquefact) or increase the amount of fresh water used for liquefaction.
  • compositions and methods relate to modified yeast that over-express fumarate-succinate transporter. Aspects and embodiments of the compositions and methods are described in the following, independently-numbered, paragraphs.
  • modified yeast cells derived from parental yeast cells comprising a genetic alteration that causes the modified cells to produce an increased amount of SFC1 polypeptides compared to the parental cells, wherein the modified cells produce during fermentation more ethanol and/or less acetate compared to the amount of ethanol and acetate produced by otherwise identical parent yeast cells.
  • the genetic alteration comprises the introduction into the parental cells of a nucleic acid capable of directing the expression of a SFC1 polypeptide to a level above that of the parental cell grown under equivalent conditions.
  • the genetic alteration comprises the introduction of an expression cassette for expressing a SFC1 polypeptide.
  • the amount of increase in the expression of the SFC1 polypeptide is at least about 500% compared to the level expression in the parental cells grown under equivalent conditions.
  • the amount of increase in the production of mRNA encoding the SFC1 polypeptide is at least about 1,000% compared to the level in the parental cells grown under equivalent conditions.
  • the amount of increase in the production of mRNA encoding the SFC1 polypeptide is at least about 5,000% compared to the level in the parental cells grown under equivalent conditions.
  • the cells further comprise an exogenous gene encoding a carbohydrate processing enzyme.
  • the modified cells of any of paragraphs 1 -7 further comprise a PKL pathway.
  • the modified cells of any of paragraphs 1-8 further comprise an alteration in the glycerol pathway and/or the acetyl-CoA pathway.
  • the modified cells of any of paragraphs 1-9 further comprise an alterative pathway for making ethanol.
  • the cells are of a Saccharomyces spp.
  • a method for increased production of alcohol and/or decreasing the production of acetate from yeast cells grown on a carbohydrate substrate comprising: introducing into parental yeast cells a genetic alteration that increases the production of SFC1 polypeptides compared to the amount produced in the parental cells.
  • the cells having the introduced genetic alteration are the modified cells are the cells of any of paragraphs 1-3 and 7-1 1.
  • the increased production of alcohol is at least 0.2%, at least 0.5%, at least 0.7% or at least 1.0%.
  • the decreased production of acetate is at least 3% at least 4%, at least 5% or at least 6%.
  • SFC1 polypeptides are over-expressed by at least 5-fold, at least 10-fold, at least 50-fold, at least 80-fold, at least 100-fold, or even at least 500-fold.
  • alcohol refers to an organic compound in which a hydroxyl functional group (-OH) is bound to a saturated carbon atom.
  • yeast cells refer to organisms from the phyla Ascomycota and Basidiomycota.
  • Exemplary yeast is budding yeast from the order Saccharomycetales.
  • Particular examples of yeast are Saccharomyces spp., including but not limited to S. cerevisiae.
  • Yeast include organisms used for the production of fuel alcohol as well as organisms used for the production of potable alcohol, including specialty and proprietary yeast strains used to make distinctive-tasting beers, wines, and other fermented beverages.
  • the phrase“engineered yeast cells,”“variant yeast cells,”“modified yeast cells,” or similar phrases, refer to yeast that include genetic modifications and characteristics described herein. Variant/modified yeast do not include naturally occurring yeast.
  • polypeptide and“protein” are used interchangeably to refer to polymers of any length comprising amino acid residues linked by peptide bonds.
  • the conventional one-letter or three-letter codes for amino acid residues are used herein and all sequence are presented from an N-terminal to C -terminal direction.
  • the polymer can comprise modified amino acids, and it can be interrupted by nonamino acids.
  • the terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component. Also included within the definition are, for example,
  • polypeptides containing one or more analogs of an amino acid including, for example, unnatural amino acids, etc., as well as other modifications known in the art.
  • proteins are considered to be “related proteins,” or“homologs.” Such proteins can be derived from organisms of different genera and/or species, or different classes of organisms (e.g., bacteria and fungi), or artificially designed. Related proteins also encompass homologs determined by primary sequence analysis, determined by secondary or tertiary structure analysis, or determined by immunological cross-reactivity, or determined by their functions.
  • homologous protein refers to a protein that has similar activity and/or structure to a reference protein. It is not intended that homologs necessarily be evolutionarily related. Thus, it is intended that the term encompass the same, similar, or corresponding enzyme(s) (i.e., in terms of structure and function) obtained from different organisms. In some embodiments, it is desirable to identify a homolog that has a quaterary, tertiary and/or primary structure similar to the reference protein. In some embodiments, homologous proteins induce similar immunological response(s) as a reference protein. In some embodiments, homologous proteins are engineered to produce enzymes with desired activity(ies).
  • the degree of homology between sequences can be determined using any suitable method known in the art (see, e.g, Smith and Waterman (1981) Adv. Appl. Math. 2:482; Needleman and Wunsch (1970) J. Mol. Biol., 48:443; Pearson and Lipman (1988) Proc. Natl. Acad. Sci. USA 85:2444; programs such as GAP, BESTFIT, FAST A, and TFASTA in the Wisconsin Genetics Software Package (Genetics Computer Group, Madison, WI); and Devereux et al. (1984) Nucleic Acids Res. 12:387-95).
  • PILEUP is a useful program to determine sequence homology levels.
  • PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pair-wise alignments. It can also plot a tree showing the clustering relationships used to create the alignment.
  • PILEUP uses a simplification of the progressive alignment method of Feng and Doolittle, (Feng and Doolittle (1987) J. Mol. Evol. 35:351-60). The method is similar to that described by Higgins and Sharp ((1989) CABIOS 5:151-53).
  • Useful PILEUP parameters including a default gap weight of 3.00, a default gap length weight of 0.10, and weighted end gaps.
  • Another example of a useful algorithm is the BLAST algorithm, described by Altschul etal.
  • BLAST program is the WU-BLAST-2 program (see, e.g. , Altschul et al. (1996) Meth. Enzymol. 266:460-80). Parameters“W,”“T,” and“X” determine the sensitivity and speed of the alignment.
  • the BLAST program uses as defaults a word-length (W) of 11, the BLOSUM62 scoring matrix (see, e.g., Henikoff and Henikoff (1989) Proc. Natl. Acad. Sci. USA 89:10915) alignments (B) of 50, expectation (E) of 10, M'5, N'-4, and a comparison of both strands.
  • the phrases“substantially similar” and“substantially identical,” in the context of at least two nucleic acids or polypeptides, typically means that a polynucleotide or polypeptide comprises a sequence that has at least about 70% identity, at least about 75% identity, at least about 80% identity, at least about 85% identity, at least about 90% identity, at least about 91% identity, at least about 92% identity, at least about 93% identity, at least about 94% identity, at least about 95% identity, at least about 96% identity, at least about 97% identity, at least about 98% identity, or even at least about 99% identity, or more, compared to the reference (i.e., wild-type) sequence.
  • Percent sequence identity is calculated using CLUSTAL W algorithm with default parameters. See Thompson et al. (1994) Nucleic Acids Res. 22:4673-4680. Default parameters for the CLUSTAL W algorithm are:
  • Gap opening penally: 10.0
  • polypeptides are substantially identical.
  • first polypeptide is immunologically cross-reactive with the second polypeptide.
  • polypeptides that differ by conservative amino acid substitutions are immunologically cross- reactive.
  • a polypeptide is substantially identical to a second polypeptide, for example, where the two peptides differ only by a conservative substitution.
  • Another indication that two nucleic acid sequences are substantially identical is that the two molecules hybridize to each other under stringent conditions (e.g, within a range of medium to high stringency).
  • the term“gene” is synonymous with the term“allele” in referring to a nucleic acid that encodes and directs the expression of a protein or RNA. Vegetative forms of filamentous fimgi are generally haploid, therefore a single copy of a specified gene (i.e., a single allele) is sufficient to confer a specified phenotype.
  • the term“allele” is generally preferred when an organism contains more than one similar genes, in which case each different similar gene is referred to as a distinct“allele.”
  • “constitutive” expression refers to the production of a polypeptide encoded by a particular gene under essentially all typical growth conditions, as opposed to “conditional” expression, which requires the presence of a particular substrate, temperature, or the like to induce or activate expression.
  • the term“expressing a polypeptide” and similar terms refers to the cellular process of producing a polypeptide using the translation machinery (e.g, ribosomes) of the cell.
  • “over-expressing a polypeptide,”“increasing the expression of a polypeptide,” and similar terms refer to expressing a polypeptide at higher-than-normal levels compared to those observed with parental or“wild-type cells that do not include a specified genetic modification.
  • an“expression cassette” refers to a DNA fragment that includes a promoter, and amino acid coding region and a terminator (i.e., promoter:: amino acid coding region: terminator) and other nucleic acid sequence needed to allow the encoded polypeptide to be produced in a cell.
  • Expression cassettes can be exogenous (i.e., introduced into a cell) or endogenous (i.e. , extant in a cell).
  • the terms“fused” and“fusion” with respect to two DNA fragments, such as a promoter and the coding region of a polypeptide refer to a physical linkage causing the two DNA fragments to become a single molecule.
  • wild-type and“native” are used interchangeably and refer to genes, proteins or strains found in nature, or that are not intentionally modified for the advantage of the presently described yeast.
  • the term“protein of interest” refers to a polypeptide that is desired to be expressed in modified yeast.
  • a protein can be an enzyme, a substrate-binding protein, a surface-active protein, a structural protein, a selectable marker, a signal transducer, a receptor, a transporter, a transcription factor, a translation factor, a co-factor, or the like, and can be expressed.
  • the protein of interest is encoded by an endogenous gene or a heterologous gene (i.e. , gene of interest”) relative to the parental strain.
  • the protein of interest can be expressed intracellularly or as a secreted protein.
  • disruption of a gene refers broadly to any genetic or chemical manipulation, i.e., mutation, that substantially prevents a cell from producing a function gene product, e.g., a protein, in a host cell.
  • exemplary methods of disruption include complete or partial deletion of any portion of a gene, including a polypeptide-coding sequence, a promoter, an enhancer, or another regulatory element, or mutagenesis of the same, where mutagenesis encompasses substitutions, insertions, deletions, inversions, and combinations and variations, thereof, any of which mutations substantially prevent the production of a function gene product.
  • a gene can also be disrupted using CRISPR, RNAi, antisense, or any other method that abolishes gene expression.
  • a gene can be disrupted by deletion or genetic manipulation of non-adjacent control elements.
  • deletion of a gene refers to its removal from the genome of a host cell.
  • control elements e.g., enhancer elements
  • deletion of a gene refers to the deletion of the coding sequence, and optionally adjacent enhancer elements, including but not limited to, for example, promoter and/or terminator sequences, but does not require the deletion of non-adjacent control elements.
  • Deletion of a gene also refers to the deletion a part of the coding sequence, or a part of promoter immediately or not immediately adjacent to the coding sequence, where there is no functional activity of the interested gene existed in the engineered cell.
  • the terms“genetic manipulation” and“genetic alteration” are used interchangeably and refer to the alteration/change of a nucleic acid sequence.
  • the alteration can include but is not limited to a substitution, deletion, insertion or chemical modification of at least one nucleic acid in the nucleic acid sequence.
  • a“functional polypeptide/protein” is a protein that possesses an activity, such as an enzymatic activity, a binding activity, a surface-active property, a signal transducer, a receptor, a transporter, a transcription factor, a translation factor, a co-factor, or the like, and which has not been mutagenized, truncated, or otherwise modified to abolish or reduce that activity.
  • Functional polypeptides can be thermostable or thermolabile, as specified.
  • a functional gene is a gene capable of being used by cellular components to produce an active gene product, typically a protein. Functional genes are the antithesis of disrupted genes, which are modified such that they cannot be used by cellular components to produce an active gene product, or have a reduced ability to be used by cellular components to produce an active gene product.
  • yeast cells have been“modified to prevent the production of a specified protein” if they have been genetically or chemically altered to prevent the production of a functional protein/polypeptide that exhibits an activity characteristic of the wild-type protein.
  • modifications include, but are not limited to, deletion or disruption of the gene encoding the protein (as described, herein), modification of the gene such that the encoded polypeptide lacks the aforementioned activity, modification of the gene to affect post-translational processing or stability, and combinations, thereof.
  • “attenuation of a pathway” or“attenuation of the flux through a pathway,” i.e., a biochemical pathway, refers broadly to any genetic or chemical
  • Attenuation of a pathway may be achieved by a variety of well-known methods. Such methods include but are not limited to: complete or partial deletion of one or more genes, replacing wild-type alleles of these genes with mutant forms encoding enzymes with reduced catalytic activity or increased Km values, modifying the promoters or other regulatory elements that control the expression of one or more genes, engineering the enzymes or the mRNA encoding these enzymes for a decreased stability, misdirecting enzymes to cellular compartments where they are less likely to interact with substrate and intermediates, the use of interfering RNA, and the like.
  • “aerobic fermentation” refers to growth in the presence of oxygen.
  • anaerobic fermentation refers to growth in the absence of oxygen.
  • “end of fermentation” refers to the stage of fermentation when the economic advantage of continuing fermentation to produce a small amount of additional alcohol is exceeded by the cost of continuing fermentation in terms of fixed and variable costs. In a more general sense,“end of fermentation” refers to the point where a fermentation will no longer produce a significant amount of additional alcohol, i.e., no more than about 1% additional alcohol, or no more substrate left for further alcohol production.
  • carbon flux refers to the rate of turnover of carbon molecules through a metabolic pathway. Carbon flux is regulated by enzymes involved in metabolic pathways, such as the pathway for glucose metabolism and the pathway for maltose metabolism.
  • SFC1 is a mitochondrial succinate-fumarate transporter; it transports succinate into and fumarate out of the mitochondrion; required for ethanol and acetate utilization (Palmieri, L. et al. (2000) Biochim Biophys Acta 1459:363-69).
  • Applicants have discovered that wild type yeast cells over-expressing SFC1 polypeptides produce an increased amount of ethanol and decreased amount of acetate compared to otherwise-identical parental cells.
  • the increase in the amount of SFC1 polypeptides produced by the modified cells is an increase of at least 500%, at least 1,000%, at least 5,000%, at least 10,000%, or at least 20,000%, or at least 50,000%, or at least 100,000%, or more, compared to the amount of SFC1 polypeptides produced by parental cells grown under the same conditions.
  • the increase in the amount of SFC1 polypeptides produced by the modified cells is at least 5-fold, at least 10-fold, at least 50-fold, at least 100-fold, at least 200-fold, at least 500-fold, at least 1,000-fold, or more, compared to the amount of SFC1 polypeptides produced by parental cells grown under the same conditions.
  • the increase in the strength of the promoter used to control expression of the SFC1 polypeptides produced by the modified cells is at least 5-fold, at least 10-fold, at least 50-fold, at least 100-fold, at least 200-fold, at least 500-fold, at least 1,000- fold, or more, compared to strength of the native promoter controlling SFC1 expression.
  • the increase in ethanol production by the modified cells is an increase of at least 0.2%, at least 0.5%, at least 0.75%, at least 0.9%, at least 1.0% or more, compared to the amount of ethanol produced by parental cells grown under the same conditions.
  • the decrease in acetate production by the modified cells is a decrease of at least 0.5%, at least 1.0%, at least 2.0%, at least 3.0%, at least 4.0%, at least 5.0%, at least 6.0%, at least 7.0%, at least 8.0%, or more, compared to the amount of acetate produced by parental cells grown under the same conditions.
  • increased SFC1 expression is achieved by genetic manipulation using sequence-specific molecular biology techniques, as opposed to chemical mutagenesis, which is generally not targeted to specific nucleic acid sequences.
  • chemical mutagenesis is not excluded as a method for making modified yeast cells.
  • the present compositions and methods involve introducing into yeast cells a nucleic acid capable of directing the over-expression, or increased expression, of a SFC1 polypeptide.
  • Particular methods include but are not limited to (i) introducing an exogenous expression cassette for producing the polypeptide into a host cell, optionally in addition to an endogenous expression cassette, (ii) substituting an exogenous expression cassette with an endogenous cassette that allows the production of an increased amount of the polypeptide, (iii) modifying the promoter of an endogenous expression cassette to increase expression, (iv) increase copy number of the same or different cassettes for over-expression of PAB1, and/or (v) modifying any aspect of the host cell to increase the half-life of the polypeptide in the host cell.
  • the parental cell that is modified already includes a gene of interest, such as a gene encoding a selectable marker, carbohydrate-processing enzyme, or other polypeptide.
  • a gene of introduced is subsequently introduced into the modified cells.
  • the parental cell that is modified already includes an engineered pathway of interest, such as a PKL pathway to increases ethanol production, or any other pathway to increase alcohol production.
  • an engineered pathway of interest such as a PKL pathway to increases ethanol production, or any other pathway to increase alcohol production.
  • the amino acid sequence of the SFC1 polypeptide that is over-expressed in modified yeast cells has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or even at least about 99% identity, to SEQ ID NO: 1.
  • amino acid sequence searching identified several known SFC1 molecules within 90% amino acid sequence identity of the exemplified molecule (i.e., SEQ ID NO: 1) with similar annotations.
  • amino acid sequence of the SFC1 polypeptide that is over-expressed in modified yeast cells has at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or even at least 99% identity, to SEQ ID NO: 1 and/or one or more of the SFC1 amino acid sequences referred to in Table 1.
  • Modified yeast cells having increased SFC1 expression in combination with genes of an exogenous PKL pathway having increased SFC1 expression in combination with genes of an exogenous PKL pathway
  • Increased expression of SFC1 can be combined with expression of genes in the PKL pathway to further increase ethanol production.
  • Engineered yeast cells having a heterologous PKL pathway have been previously described in WO2015148272 (Miasnikov et al). These cells express heterologous phosphoketolase (PKL), phosphotransacetylase (PTA) and acetylating acetyl dehydrogenase (AADH), optionally with other enzymes, to channel carbon flux away from the glycerol pathway and toward the synthesis of acetyl-CoA, which is then converted to ethanol.
  • PTL heterologous phosphoketolase
  • PTA phosphotransacetylase
  • AADH acetylating acetyl dehydrogenase
  • Such modified cells are capable of increased ethanol production in a fermentation process when compared to otherwise-identical parent yeast cells.
  • the present modified yeast cells include additional beneficial modifications.
  • the modified cells may further include mutations that result in attenuation of the native glycerol biosynthesis pathway and/or reuse glycerol pathway, which are known to increase alcohol production.
  • Methods for attenuation of the glycerol biosynthesis pathway in yeast are known and include reduction or elimination of endogenous NAD-dependent glycerol 3-phosphate dehydrogenase (GPD) or glycerol phosphate phosphatase activity (GPP), for example by disruption of one or more of the genes GPDl, GPD2, GPP1 and/or GPP2. See, e.g., U.S. Patent Nos.
  • the modified yeast may further feature increased acetyl-CoA synthase (also referred to acetyl-CoA ligase) activity (EC 6.2.1.1) to scavenge (i.e., capture) acetate produced by chemical or enzymatic hydrolysis of acetyl-phosphate (or present in the culture medium of the yeast for any other reason) and converts it to Ac-CoA.
  • acetyl-CoA synthase also referred to acetyl-CoA ligase activity
  • scavenge i.e., capture
  • Increasing acetyl-CoA synthase activity may be accomplished by introducing a heterologous acetyl-CoA synthase gene into cells, increasing the expression of an endogenous acetyl-CoA synthase gene and the like.
  • the modified cells may further include a heterologous gene encoding a protein with NAD + -dependent acetylating acetaldehyde dehydrogenase activity and/or a heterologous gene encoding a pyruvate-formate lyase.
  • a heterologous gene encoding a protein with NAD + -dependent acetylating acetaldehyde dehydrogenase activity and/or a heterologous gene encoding a pyruvate-formate lyase.
  • the yeast expressly lacks a heterologous gene(s) encoding an acetylating acetaldehyde dehydrogenase, a pyruvate-formate lyase or both.
  • the present modified yeast cells may further over-express a sugar transporter-like (STL1) polypeptide to increase the uptake of glycerol (see, e.g., STL1) polypeptide to increase the uptake of glycerol (see, e.g., STL1
  • the present modified yeast cells further include a butanol biosynthetic pathway.
  • the butanol biosynthetic pathway is an isobutanol biosynthetic pathway.
  • the isobutanol biosynthetic pathway comprises a polynucleotide encoding a polypeptide that catalyzes a substrate to product conversion selected from the group consisting of: (a) pyruvate to acetolactate; (b) acetolactate to 2,3-dihydroxyisovalerate; (c) 2,3-dihydroxyisovalerate to 2-ketoisovalerate; (d) 2- ketoisovalerate to isobutyraldehyde; and (e) isobutyraldehyde to isobutanol.
  • the isobutanol biosynthetic pathway comprises polynucleotides encoding polypeptides having acetolactate synthase, keto acid reductoisomerase, dihydroxy acid dehydratase, ketoisovalerate decarboxylase, and alcohol dehydrogenase activity.
  • the modified yeast cells comprising a butanol biosynthetic pathway further comprise a modification in a polynucleotide encoding a polypeptide having pyruvate decarboxylase activity.
  • the yeast cells comprise a deletion, mutation, and/or substitution in an endogenous polynucleotide encoding a polypeptide having pyruvate decarboxylase activity.
  • the polypeptide having pyruvate decarboxylase activity is selected from the group consisting of: PDC1, PDC5, PDC6, and combinations thereof.
  • the yeast cells further comprise a deletion, mutation, and/or substitution in one or more endogenous polynucleotides encoding FRA2, ALD6, ADH1, GPD2, BDH1, and YMR226C.
  • the present modified yeast cells further include any number of additional genes of interest encoding proteins of interest. Additional genes of interest may be introduced before, during, or after genetic manipulations that result in the increased production of SFC1 polypeptides.
  • Proteins of interest include selectable markers, carbohydrate-processing enzymes, and other commercially-relevant polypeptides, including but not limited to an enzyme selected from the group consisting of a dehydrogenase, a transketolase, a phosphoketolase, a transladolase, an epimerase, a phytase, a xylanase, a b- glucanase, a phosphatase, a protease, an a-amylase, a b-amylase, a glucoamylase, a pullulanase, an isoamylase, a cellulase, a trehalase, a lipase, a pectinase, a polyesterase, a cutinase, an oxidase, a transferase, a reductase, a hemi cellulase, a mannana
  • the present compositions and methods include methods for increasing alcohol production and/or reducing glycerol production, in fermentation reactions. Such methods are not limited to a particular fermentation process.
  • the present engineered yeast is expected to be a“drop-in” replacement for convention yeast in any alcohol fermentation facility. While primarily intended for fuel alcohol production, the present yeast can also be used for the production of potable alcohol, including wine and beer.
  • Yeasts are unicellular eukaryotic microorganisms classified as members of the fungus kingdom and include organisms from the phyla Ascomycota and Basidiomycota. Yeast that can be used for alcohol production include, but are not limited to, Saccharomyces spp., including S. cerevisiae, as well as Kluyveromyces, Lachancea and Schizosaccharomyces spp. Numerous yeast strains are commercially available, many of which have been selected or genetically engineered for desired characteristics, such as high alcohol production, rapid growth rate, and the like. Some yeasts have been genetically engineered to produce heterologous enzymes, such as glucoamylase or a-amylase.
  • Alcohol fermentation products include organic compound having a hydroxyl functional group (-OH) is bound to a carbon atom
  • exemplary alcohols include but are not limited to methanol, ethanol, «-propanol, isopropanol, «-butanol, isobutanol, n-pentanol, 2- pentanol, isopentanol, and higher alcohols.
  • the most commonly made fuel alcohols are ethanol, and butanol.
  • Liquefact (com mash slurry) was prepared by adding 600 ppm of urea, 0.124 SAPU/g ds acid fungal protease, 0.33 GAU/g ds variant Trichoderma reesei glucoamylase and 1.46 SSCU/g ds Aspergillus kawachii a-amylase, adjusted to a pH of 4.8 with sulfuric acid.
  • RPK1 OM reads per kilobase ten million transcripts
  • RNA-Seq analysis was performed to identify a promoter for over-expression of SFC 1 during fermentation. Analysis was performed as described in Example 1. The results summarized in Table 2 report expression levels as reads per kilobase ten million transcripts (RPKIOM). There was almost no expression of SFC1 in FERMAXTM Gold (Martrex Inc., Minnesota, USA; herein abbreviated, "FG”) 6 hr into fermentation, and only modest expression 24 hr into fermentation. In contrast, the elongation factor 1-b (EFB1) gene was highly expressed at 6 hr and 24 hr into fermentation. Accordingly, the EFB1 promoter was selected for overexpressing SFC1 in yeast.
  • FERMAXTM Gold Martrex Inc., Minnesota, USA; herein abbreviated, "FG”
  • FG elongation factor 1-b
  • the SFC1 gene (YJR095W locus, SEQ ID: 2) of Saccharomyces cerevisiae was synthesized to generate SFCls.
  • the EFB1 promoter (YAL003W locus; SEQ ID NO: 3) and FBA1 terminator (YKL060C locus; SEQ ID NO: 4) were operably linked to the coding sequence to generate the EFBlPro::SFCls s::FbalTer expression cassette.
  • This expression cassette was introduced at position 350000 of Chromosome II of FERMAXTM Gold (Martrex Inc., Minnesota, USA; herein abbreviated,“FG”), a well-known fermentation yeast used in the grain ethanol industry.
  • the expected insertion of the SFCls expression cassette in the two parental strains was confirmed by PCR.
  • the amino acid sequence of the SFCls polypeptide is shown, below, as SEQ ID NO: 1:

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des compositions et des procédés se rapportant à une levure modifiée qui surexprime le transporteur fumarate-succinate. La levure produit une quantité accrue d'éthanol et une quantité réduite d'acétate par rapport aux cellules parentales. Une telle levure est particulièrement utile pour la production d'éthanol à grande échelle à partir de substrats d'amidon où l'acétate est un sous-produit indésirable.
EP20718458.1A 2019-03-14 2020-03-14 Surexpression du transporteur fumarate-succinate dans la levure pour augmenter la production d'éthanol et réduire la production d'acétate Pending EP3938519A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962818471P 2019-03-14 2019-03-14
PCT/US2020/022853 WO2020186254A1 (fr) 2019-03-14 2020-03-14 Surexpression du transporteur fumarate-succinate dans la levure pour augmenter la production d'éthanol et réduire la production d'acétate

Publications (1)

Publication Number Publication Date
EP3938519A1 true EP3938519A1 (fr) 2022-01-19

Family

ID=70277486

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20718458.1A Pending EP3938519A1 (fr) 2019-03-14 2020-03-14 Surexpression du transporteur fumarate-succinate dans la levure pour augmenter la production d'éthanol et réduire la production d'acétate

Country Status (2)

Country Link
EP (1) EP3938519A1 (fr)
WO (1) WO2020186254A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2060632A1 (fr) 2007-10-29 2009-05-20 Technische Universität Berlin Procédé pour la modification d'une cellule de levure pour la production d'éthanol
EP2277989A1 (fr) 2009-07-24 2011-01-26 Technische Universiteit Delft Production d'éthanol dépourvu de glycérol par fermentation
BR122019017739B1 (pt) 2011-04-05 2021-06-22 Lallemand Hungary Liquidity Management Llc Micro-organismo recombinante compreendendo uma deleção de enzimas nativas que atuam para produzir glicerol e/ou regular a síntese de glicerol e vias metabólicas sintéticas para converter uma fonte de carboidrato a etanol
EP3033413B2 (fr) 2013-08-15 2023-05-10 Lallemand Hungary Liquidity Management LLC Procédés pour l'amélioration du rendement de production et de la production dans un micro-organisme par recyclage de glycérol
EP3122876B1 (fr) 2014-03-28 2020-11-25 Danisco US Inc. Voie de cellule hôte modifiée pour la production améliorée d'éthanol

Also Published As

Publication number Publication date
WO2020186254A1 (fr) 2020-09-17

Similar Documents

Publication Publication Date Title
US11447783B2 (en) Reduction in acetate production by yeast over-expressing PAB1
AU2020391450A1 (en) Reduction in acetate production by yeast over-expressing MIG polypeptides
WO2020069067A1 (fr) Surexpression de l'inhibiteur de la ribonucléotide réductase dans la levure pour une production accrue d'éthanol
EP3802784A1 (fr) Surexpression de l'activateur/répresseur transcriptionnel gis1 dans la levure pour une production accrue d'éthanol
WO2019173225A1 (fr) Levures présentant une production d'alcool améliorée dans des conditions à teneur élevée en solides dissous
WO2019173217A1 (fr) Compositions et procédés pour augmenter la production d'éthanol par une levure à l'aide de gcy1 et de dak1
WO2020186254A1 (fr) Surexpression du transporteur fumarate-succinate dans la levure pour augmenter la production d'éthanol et réduire la production d'acétate
CN112041449B (zh) 通过过表达pab1的酵母来降低乙酸生产
EP3938381A1 (fr) Surexpression du cytochrome b2 dans la levure pour une production accrue d'éthanol
WO2021022140A1 (fr) Surexpression de pho13 pour augmenter la production d'éthanol par la levure
EP4355881A1 (fr) Production accrue d'éthanol par surexpression de kgd2 dans la levure
US20230116556A1 (en) Increased ethanol production by overexpression of jid1 in yeast
WO2023076323A1 (fr) Réduction de l'acétate produite par la levure avec une expression réduite de rsf2 ou de tda9
WO2021022097A1 (fr) Surexpression de l'adh5p pour augmenter la production d'éthanol par la levure
US20230331789A1 (en) Over-expression of gds1 in yeast for increased ethanol and decreased acetate production
US20210032642A1 (en) Increased alcohol production from yeast producing an increased amount of active hac1 protein
US20210147792A1 (en) Yeast over-expressing protein phosphatases associated with the hog pathway
WO2024123691A1 (fr) Production accrue d'éthanol par levure dans des solides à haute dissolution
EP3802801A1 (fr) Surexpression de fumarate réductase conduisant à une vitesse de fermentation accrue dans la levure
WO2020068907A1 (fr) Gènes sélectionnés de phosphotransacétylase pour une production accrue d'éthanol dans une levure modifiée
EP3665266A1 (fr) Production accrue d'éthanol par une levure présentant des allèles mal
WO2018136385A1 (fr) Cellules de levure modifiées qui surexpriment une sous-unité d'adn polymérase

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211014

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230530